Cognizant
CTSH
$55.10
-6.31%
Cognizant Technology Solutions is a multinational IT services and consulting provider, operating within the Information Technology Services industry, offering a range of digital, consulting, and business process outsourcing services to enterprise clients globally. The company is a major player in the global IT services landscape, leveraging a significant offshore workforce primarily in India to deliver cost-effective solutions, and it is distinct as a US-headquartered firm with deep roots in the Indian IT services model, competing directly with giants like Infosys and Accenture. The current investor narrative revolves around the company's ability to navigate a challenging demand environment marked by client spending caution, as evidenced by recent quarterly results, while simultaneously executing a strategic shift towards higher-value digital services to drive future growth and margin expansion.…
CTSH
Cognizant
$55.10
Investment Opinion: Should I buy CTSH Today?
Rating & Thesis: Hold. CTSH presents a compelling valuation case but lacks the near-term catalysts and growth momentum to warrant a Buy rating, aligning with the cautious 'Hold' and 'Sector Perform' stance observed among analysts. The core thesis is that the stock is undervalued based on forward earnings and financial strength, but it is a 'value trap' until revenue growth stabilizes or reaccelerates.
Supporting Evidence: The primary valuation metric, the forward P/E of 10.0x, is exceptionally low and implies a significant earnings recovery from estimated EPS of $6.26. The company's robust balance sheet, with a debt-to-equity of 0.10 and a current ratio of 2.34, provides a solid foundation. Strong free cash flow generation of $2.60B TTM supports shareholder returns. However, these positives are counterbalanced by decelerating revenue growth (4.94% YoY in Q4) and severe technical damage, with the stock down 27.66% over three months.
Risks & Conditions: The two biggest risks are persistent revenue deceleration and a failure to stabilize margins. This Hold rating would upgrade to a Buy if the forward P/E compresses further towards 8x without a deterioration in fundamentals, or if the company reports a return to mid-single-digit or better revenue growth for two consecutive quarters. It would downgrade to a Sell if revenue growth turns negative or if the stock decisively breaks below the $57.39 support level on worsening fundamentals. The stock is currently fairly valued to slightly undervalued relative to its own depressed history, but overvalued relative to its near-term growth trajectory.
Sign up to view all
CTSH 12-Month Price Forecast
The AI assessment is neutral with medium confidence. CTSH is a bifurcated story: its valuation and balance sheet are profoundly attractive, but its growth trajectory and price momentum are deeply concerning. The low forward P/E provides a significant margin of safety, making severe further downside less likely unless fundamentals deteriorate markedly. However, for a sustained rally, evidence of a growth inflection is required. The stance would upgrade to bullish on confirmation of revenue stabilization and a technical reversal above the $70 level. It would turn bearish on a breakdown below $57 with concurrent negative revisions to forward earnings estimates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cognizant's 12-month outlook, with a consensus price target around $71.63 and implied upside of +30.0% versus the current price.
Average Target
$71.63
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$44 - $72
Analyst target range
Analyst coverage for CTSH is limited, with only 9 analysts providing estimates, indicating this is not a widely covered mega-cap stock, which can lead to higher volatility and less efficient price discovery. The available data provides consensus estimates for EPS and revenue but does not include a consensus price target, Buy/Hold/Sell distribution, or a target price range, making it impossible to calculate implied upside or gauge the directional sentiment from the analyst community. The lack of explicit price targets and recommendations suggests investors must rely more heavily on their own fundamental and valuation work; the recent institutional rating actions show a mix of 'Hold', 'Sector Perform', and a few 'Buy' or 'Overweight' ratings, with no major downgrades in early 2026, indicating a generally cautious but not bearish stance among those who do publish research on the stock.
Bulls vs Bears: CTSH Investment Factors
The evidence presents a classic value vs. momentum conflict. The bear case is currently stronger on a technical and near-term fundamental basis, as evidenced by the severe price decline, revenue deceleration, and negative relative strength. However, the bull case is compelling from a valuation and financial health perspective, with a rock-solid balance sheet and a forward P/E that prices in significant pessimism. The single most important tension in the investment debate is whether the company's strategic shift to higher-value digital services can reignite sustainable growth before valuation compression fully reflects the operational headwinds. The resolution of this growth trajectory will determine if the current price represents a value trap or a genuine turnaround opportunity.
Bullish
- Deeply Undervalued Forward P/E: The stock trades at a forward P/E of 10.0x based on estimated EPS of $6.26, which is a significant discount to its trailing P/E of 17.9x. This low multiple suggests the market has priced in very pessimistic earnings expectations, creating a potential value opportunity if the company meets or exceeds these estimates.
- Strong Balance Sheet and Cash Flow: CTSH has a robust financial position with a low debt-to-equity ratio of 0.10 and a current ratio of 2.34. The company generates substantial free cash flow ($2.60B TTM), providing ample liquidity to fund operations, dividends, and share buybacks without financial strain.
- Attractive Valuation Relative to History: The current trailing P/E of 17.9x is near the lower end of its recent historical range (11.78x to 29.74x). Trading near a 52-week low of $57.39, the stock appears oversold, potentially offering a margin of safety for value-oriented investors.
- Stable Profitability in Core Operations: Despite recent volatility, the company maintains a healthy operating margin of 16.72% and a TTM net margin of 10.56%. The Q4 2025 net income of $648M demonstrates the underlying profitability of its IT services business model.
Bearish
- Severe Technical Downtrend and Underperformance: The stock is down 27.66% over the last three months and 11.72% over the past year, significantly underperforming the S&P 500 by 46.62%. This persistent selling pressure and a maximum drawdown of -33.19% indicate deep-seated investor concerns and a lack of positive momentum.
- Revenue Growth Deceleration: Q4 2025 revenue growth slowed to 4.94% YoY, a deceleration from stronger prior quarters. This slowdown reflects the challenging demand environment in IT services, where clients are exhibiting spending caution, threatening future top-line expansion.
- Earnings Volatility and Margin Pressure: Net income dropped sharply to $274M in Q3 2025 (5.06% margin) due to a large tax expense, highlighting earnings volatility. Furthermore, the latest quarterly gross margin of 31.11% is below the TTM average of 33.72%, indicating potential competitive or pricing pressure.
- Limited Analyst Coverage and Sentiment: With only 9 analysts providing estimates and no consensus price target available, CTSH suffers from lower visibility and potentially less efficient price discovery. The mix of 'Hold' and 'Sector Perform' ratings suggests a cautious, non-committal stance from the professional community.
CTSH Technical Analysis
The stock is in a pronounced downtrend, having declined 11.72% over the past year and a severe 27.66% over the last three months, significantly underperforming the broader market. Currently trading at $61.30, the price sits near the lower end of its 52-week range of $57.39 to $87.03, positioning it at approximately 10% above the 52-week low, which suggests the stock is in deeply oversold territory and may represent a value opportunity, though it also risks being a 'falling knife' if fundamental headwinds persist. Recent momentum shows a slight divergence, with a modest 1.68% gain over the past month, which contrasts sharply with the steep 3-month and 6-month losses of 27.66% and 7.23%, respectively; this short-term uptick could signal a tentative stabilization or a dead-cat bounce, but it remains against the backdrop of severe negative relative strength, underperforming the S&P 500 by 46.62% over the past year. Key technical support is firmly established at the 52-week low of $57.39, while resistance lies at the recent breakdown level near the 52-week high of $87.03; a decisive break below $57.39 would likely trigger further selling, whereas a sustained move above recent highs near $85 would be needed to signal a trend reversal. With a beta of 0.976, the stock exhibits market-like volatility, but its recent price action, including a maximum drawdown of -33.19%, indicates it has experienced idiosyncratic risk and significant selling pressure independent of the broader market's positive performance.
Beta
0.98
0.98x market volatility
Max Drawdown
-36.5%
Largest decline past year
52-Week Range
$54-$87
Price range past year
Annual Return
-22.4%
Cumulative gain past year
| Period | CTSH Return | S&P 500 |
|---|---|---|
| 1m | -8.5% | +8.5% |
| 3m | -34.5% | +2.8% |
| 6m | -18.8% | +4.6% |
| 1y | -22.4% | +32.3% |
| ytd | -32.2% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTSH Fundamental Analysis
Revenue growth has been modest but is showing signs of deceleration; Q4 2025 revenue was $5.33 billion, representing a year-over-year growth of 4.94%, but this marks a slowdown from the stronger growth rates seen in prior quarters of 2025, and segment data indicates Healthcare ($1.62B) and Financial Services ($1.59B) are the largest revenue contributors, though specific growth rates by segment are not available to pinpoint drivers or drags. The company remains profitable with a Q4 2025 net income of $648 million and a net margin of 12.15%, but profitability is volatile, as evidenced by a significant drop in Q3 2025 net income to $274 million (net margin of 5.06%) due to a large income tax expense; gross margin for the latest quarter was 31.11%, which is below the trailing twelve-month gross margin of 33.72%, indicating some recent compression, though the operating margin of 16.72% remains healthy for the industry. Balance sheet health is strong, with a low debt-to-equity ratio of 0.10 and a robust current ratio of 2.34, indicating ample liquidity; the company generates substantial cash flow, with trailing twelve-month free cash flow of $2.60 billion and an ROE of 14.85%, demonstrating it can fund operations, dividends, and share buybacks internally without reliance on excessive debt, thereby presenting low financial risk.
Quarterly Revenue
$5.3B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.31%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTSH Overvalued?
Given the company's consistent profitability, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 17.90x, while the forward PE is significantly lower at 10.00x, based on estimated EPS of $6.26; this substantial gap implies the market expects a meaningful recovery in earnings growth over the next twelve months, pricing in the anticipated improvement from recent depressed levels. Compared to sector averages, the stock's trailing PE of 17.90x and forward PE of 10.00x are not directly comparable without a provided industry average, but the forward multiple appears low on an absolute basis, potentially indicating a discount if growth expectations are met; the Price-to-Sales ratio of 1.89x and EV/EBITDA of 9.49x also suggest a reasonable valuation relative to cash flow generation. Historically, the current trailing PE of 17.90x is below the stock's own historical range observed in the provided data, which has seen PE ratios fluctuate between approximately 11.78x and 29.74x over recent quarters; trading near the lower end of this historical band suggests the market is pricing in pessimistic expectations, possibly creating a value opportunity if the company can execute its turnaround and stabilize earnings.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Cognizant faces risks from earnings volatility, as seen in the Q3 2025 net income plunge to $274M from $645M the prior quarter, primarily due to a large tax expense. While the balance sheet is strong, margin compression is a concern, with the latest quarterly gross margin of 31.11% falling below the TTM average of 33.72%. Revenue growth deceleration to 4.94% YoY in Q4 2025 indicates sensitivity to client IT spending cycles, and the company's valuation relies on a projected earnings recovery to justify its forward P/E of 10x.
Market & Competitive Risks: The stock trades at a significant discount to its own historical valuation range, but this compression could persist if growth fails to materialize. As an IT services firm with a beta of 0.976, it is exposed to broader economic cycles that dictate corporate capital expenditure. Intense competition from larger peers like Accenture and Infosys in a cost-conscious environment pressures pricing and margins. The stock's severe underperformance (-46.62% vs. SPY over 1 year) suggests it is already pricing in these sector headwinds, but further negative news could lead to additional multiple contraction.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current downtrend, where slowing revenue growth couples with sustained margin pressure, leading to consecutive earnings misses. This could trigger a loss of investor confidence, pushing the stock to test and break its 52-week low of $57.39. A breach of this key technical support could catalyze further selling, potentially driving the price down to levels implied by a forward P/E in the single digits. From the current price of $61.30, a realistic downside in this adverse scenario is a decline of approximately -20% to -25%, revisiting the $57-$60 range or lower, representing a tangible capital loss for investors.
FAQ
The key risks are, in order of severity: 1) Growth Risk: Continued deceleration or stagnation in revenue growth, as seen in the latest 4.94% YoY figure, which could lead to further multiple compression. 2) Competitive/Margin Risk: Intense competition in IT services pressuring pricing and margins, evidenced by the quarterly gross margin drop to 31.11%. 3) Technical/Momentum Risk: The stock is in a pronounced downtrend with a -33.19% max drawdown, indicating persistent selling pressure that can continue irrespective of fundamentals. 4) Sentiment Risk: Limited analyst coverage (9 analysts) and lack of clear bullish catalysts can lead to prolonged investor apathy and underperformance.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $65 and $75, assuming low-single-digit growth and a stable forward P/E around 10x-12x. The Bull Case (25% probability) targets $80 to $87, driven by a growth reacceleration and P/E expansion. The Bear Case (15% probability) warns of a drop to the $57 to $62 range if growth slows further and support breaks. The most likely outcome is the Base Case, where the stock grinds higher from deeply oversold levels but remains capped by modest growth, with the key assumption being that the company meets its current EPS estimate of $6.26.
CTSH appears significantly undervalued based on forward earnings, trading at a P/E of 10.0x for estimated EPS of $6.26. This is near the bottom of its own historical P/E range (11.78x to 29.74x). On an absolute basis, a sub-10x forward multiple for a profitable, cash-generative market leader is cheap. However, this discount reflects justified market skepticism about future growth. Compared to its current low-single-digit growth trajectory, the stock is fairly valued. The valuation implies the market expects minimal growth or potential earnings disappointment, creating a disconnect that offers opportunity if the company can outperform these low expectations.
CTSH is a good buy for a specific type of investor: the patient value seeker. At a forward P/E of 10.0x and with a fortress balance sheet (D/E 0.10), the stock offers a compelling valuation case and a significant margin of safety. However, it is not a good buy for momentum or growth investors, as revenue growth is decelerating (4.94% YoY) and the stock is in a severe downtrend (-27.66% over 3 months). The investment carries the risk of being a 'value trap' if operational headwinds persist. It is a good buy only for those willing to hold for 12-24 months awaiting a potential turnaround.
CTSH is unsuitable for short-term trading due to its high volatility (beta 0.976), negative momentum, and lack of near-term catalysts. It is a candidate for a long-term (2+ year) investment for investors believing in a eventual operational turnaround and valuation mean reversion. The company's strong cash flow and low dividend yield (1.53%) support a long-term holder, but earnings visibility is currently low. A concrete suggested minimum holding period is 12-18 months to allow for the execution of its strategic shift and for the market to recognize any improvement in fundamentals.